Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Adagrasib: First Approval
Sohita Dhillon
Drugs (2023) Vol. 83, Iss. 3, pp. 275-285
Closed Access | Times Cited: 82

Showing 1-25 of 82 citing articles:

Emerging and Re-emerging Warheads for Targeted Covalent Inhibitors: An Update
Laura Hillebrand, Xiaojun Julia Liang, Ricardo Augusto Massarico Serafim, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 10, pp. 7668-7758
Closed Access | Times Cited: 46
Recent Advances in Covalent Drug Discovery
D. M. Schaefer, Xinlai Cheng
Pharmaceuticals (2023) Vol. 16, Iss. 5, pp. 663-663
Open Access | Times Cited: 42
Erianin inhibits the growth and metastasis through autophagy-dependent ferroptosis in KRASG13D colorectal cancer
Qun Miao, Wei-Qing Deng, Wen-Yu Lyu, et al.
Free Radical Biology and Medicine (2023) Vol. 204, pp. 301-312
Closed Access | Times Cited: 32
Circulating microRNAs as Potential Biomarkers in Pancreatic Cancer—Advances and Challenges
Attila A. Seyhan
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 17, pp. 13340-13340
Open Access | Times Cited: 29
Efficacy of immunotherapy in patients with oncogene-driven non-small-cell lung cancer: a systematic review and meta-analysis
Jiayan Chen, Wanjun Lu, Mo Chen, et al.
Therapeutic Advances in Medical Oncology (2024) Vol. 16
Open Access | Times Cited: 13
Farnesyl-transferase inhibitors show synergistic anticancer effects in combination with novel KRAS-G12C inhibitors
Marcell Baranyi, Eszter Molnár, Luca Hegedűs, et al.
British Journal of Cancer (2024) Vol. 130, Iss. 6, pp. 1059-1072
Open Access | Times Cited: 12
If it’s a target, it’s a pan-cancer target: Tissue is not the issue
Jacob J. Adashek, Shumei Kato, Jason K. Sicklick, et al.
Cancer Treatment Reviews (2024) Vol. 125, pp. 102721-102721
Open Access | Times Cited: 11
The significance of chirality in contemporary drug discovery-a mini review
Narmatha Senkuttuvan, Boopathi Komarasamy, Rajavenkatesh Krishnamoorthy, et al.
RSC Advances (2024) Vol. 14, Iss. 45, pp. 33429-33448
Open Access | Times Cited: 10
Synthetic Approaches to the New Drugs Approved During 2022
Scott P. France, Erick A. Lindsey, Emma L. McInturff, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 6, pp. 4376-4418
Closed Access | Times Cited: 9
Multitargeting HDAC Inhibitors Containing a RAS/RAF Protein Interfering Unit
Yuanjiang Wang, Jianluo Zhang, Kun Li, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 3, pp. 2066-2082
Closed Access | Times Cited: 8
Pooled safety analysis and management of sotorasib-related adverse events in KRAS G12C-mutated advanced non-small cell lung cancer
Ferdinandos Skoulidis, Bob T. Li, Maximilian J. Hochmair, et al.
The Oncologist (2025) Vol. 30, Iss. 1
Open Access | Times Cited: 1
Targeting RAF dimers in RAS mutant tumors: From biology to clinic
Huanhuan Yin, Qiulin Tang, Hongwei Xia, et al.
Acta Pharmaceutica Sinica B (2024) Vol. 14, Iss. 5, pp. 1895-1923
Open Access | Times Cited: 6
A comprehensive review of small molecule drugs approved by the FDA in 2023: Advances and prospects
Yi‐Ru Bai, Dong‐Jie Seng, Ying Xu, et al.
European Journal of Medicinal Chemistry (2024) Vol. 276, pp. 116706-116706
Closed Access | Times Cited: 6
New insights into protein–protein interaction modulators in drug discovery and therapeutic advance
Hossam Nada, Yongseok Choi, Sung-Do Kim, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 6
KRAS inhibitors: resistance drivers and combinatorial strategies
Tamara Isermann, Christine Sers, Channing J. Der, et al.
Trends in cancer (2024)
Open Access | Times Cited: 6
Targeting KRAS in Colorectal Cancer: A Bench to Bedside Review
Fernand Bteich, Mahshid Mohammadi, T. Li, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 15, pp. 12030-12030
Open Access | Times Cited: 14
Natural products targeting RAS by multiple mechanisms and its therapeutic potential in cancer: An update since 2020
Yanqing Liu, Jie Chen, Xiang Li, et al.
Pharmacological Research (2025) Vol. 212, pp. 107577-107577
Open Access
Targeting KRAS G12C and G12S Mutations in Lung Cancer: In Silico Drug Repurposing and Antiproliferative Assessment on A549 Cells
Mansour S. Alturki, Nada Tawfeeq, Amal Alissa, et al.
Informatics in Medicine Unlocked (2025), pp. 101612-101612
Open Access
Anti-proteolytic regulation of KRAS by USP9X/NDRG3 in KRAS-driven cancer development
Han Koo, Kyung Chan Park, Hyun Ahm Sohn, et al.
Nature Communications (2025) Vol. 16, Iss. 1
Open Access
Sotorasib resistance triggers epithelial-mesenchymal transition and activates AKT and P38-mediated signaling
Raquel Megid, Guilherme Ribeiro, Izabela Natália Faria Gomes, et al.
Frontiers in Molecular Biosciences (2025) Vol. 12
Open Access
Progress of KRAS G12C inhibitors in the treatment of refractory colorectal cancer and strategies for drug resistance response
Peiyuan Yang, Yongchao Li
Investigational New Drugs (2025)
Closed Access
Reducing pERKs to Break “RAS”istance to Sotorasib
Steven G. Gray, Derbrenn O'Connor, Luciano Mutti, et al.
Journal of Thoracic Oncology (2025) Vol. 20, Iss. 3, pp. 259-261
Closed Access
Structural insights, regulation, and recent advances of RAS inhibitors in the MAPK signaling cascade: a medicinal chemistry perspective
Vimal H. Prajapati, Ankit Kumar Singh, Adarsh Kumar, et al.
RSC Medicinal Chemistry (2025)
Closed Access
Integrating epidemiology and genomics data to estimate the prevalence of acquired cysteine drug targets in the U.S. cancer patient population.
Adith S. Arun, David Liarakos, Gaurav Mendiratta, et al.
PubMed (2025) Vol. 25, Iss. 1-2, pp. 5-5
Closed Access
SOS1 inhibitor BI-3406 shows in vivo antitumor activity akin to genetic ablation and synergizes with a KRAS G12D inhibitor in KRAS LUAD
Fernando C. Baltanás, Maximilian Kramer‐Drauberg, Rósula García‐Navas, et al.
Proceedings of the National Academy of Sciences (2025) Vol. 122, Iss. 11
Open Access
Page 1 - Next Page

Scroll to top